BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25004342)

  • 1. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction.
    Herraiz I; Dröge LA; Gómez-Montes E; Henrich W; Galindo A; Verlohren S
    Obstet Gynecol; 2014 Aug; 124(2 Pt 1):265-273. PubMed ID: 25004342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.
    Stepan H; Hund M; Gencay M; Denk B; Dinkel C; Kaminski WE; Wieloch P; Semus B; Meloth T; Dröge LA; Verlohren S
    Hypertens Pregnancy; 2016 Aug; 35(3):295-305. PubMed ID: 27028698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
    Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
    Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of adverse perinatal outcome and the mean time until delivery in twin pregnancies with suspected pre-eclampsia using sFlt-1/PIGF ratio.
    Karge A; Seiler A; Flechsenhar S; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B; Graupner O
    Pregnancy Hypertens; 2021 Jun; 24():37-43. PubMed ID: 33647841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction.
    Dathan-Stumpf A; Czarnowsky V; Hein V; Andraczek T; Stepan H
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1037-S1047.e2. PubMed ID: 33892922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol.
    Hund M; Allegranza D; Schoedl M; Dilba P; Verhagen-Kamerbeek W; Stepan H
    BMC Pregnancy Childbirth; 2014 Sep; 14():324. PubMed ID: 25230734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.
    Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes.
    Bednarek-Jędrzejek M; Kwiatkowski S; Ksel-Hryciów J; Tousty P; Nurek K; Kwiatkowska E; Cymbaluk-Płoska A; Torbé A
    J Perinat Med; 2019 Sep; 47(7):732-740. PubMed ID: 31339858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies.
    Saleh L; Tahitu SIM; Danser AHJ; van den Meiracker AH; Visser W
    Pregnancy Hypertens; 2018 Oct; 14():222-227. PubMed ID: 29678353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction.
    Dymara-Konopka W; Laskowska M; Grywalska E; Hymos A; Błażewicz A; Leszczyńska-Gorzelak B
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.
    Müller A; Horvat V; Vulin M; Mandić S; Šerić V; Vidosavljević D
    Med Glas (Zenica); 2019 Feb; 16(1):53-59. PubMed ID: 30680983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison.
    Andersen LB; Frederiksen-Møller B; Work Havelund K; Dechend R; Jørgensen JS; Jensen BL; Nielsen J; Lykkedegn S; Barington T; Christesen HT
    J Am Soc Hypertens; 2015 Feb; 9(2):86-96. PubMed ID: 25600419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia.
    Turpin CA; Sakyi SA; Owiredu WK; Ephraim RK; Anto EO
    BMC Pregnancy Childbirth; 2015 Aug; 15():189. PubMed ID: 26303772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
    Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?
    Zhang K; Zen M; Popovic NL; Lee VW; Alahakoon TI
    J Obstet Gynaecol Res; 2019 Sep; 45(9):1828-1836. PubMed ID: 31257726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
    Vatten LJ; Åsvold BO; Eskild A
    Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study.
    Dröge LA; Perschel FH; Stütz N; Gafron A; Frank L; Busjahn A; Henrich W; Verlohren S
    Hypertension; 2021 Feb; 77(2):461-471. PubMed ID: 33280406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.